Pradžia › Ūmi limfoblastinė leukemija › Masčusetsas
Ūmi limfoblastinė leukemija klinikiniai tyrimai Masčusetsas
15 tyrimai dėl Ūmi limfoblastinė leukemija ieško dalyvių vietose Masčusetsas.
Miestai Masčusetsas
Oficialus tyrimo tekstas (anglų kalba)
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
- Dana-Farber/Boston Children s Hospital, Boston
Renkami dalyviai
Amžius nuo 1 iki 25 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05621291Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Amžius nuo 16 iki 75 · Visoms lytims · Atnaujinta 2026-09-10 · NCT03104491The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1/2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT04726241ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 51 · Visoms lytims · Atnaujinta 2026-08-17 · NCT07227584Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Children's Hospital Corporation d/b/a Boston Children's Hospital, Boston
Renkami dalyviaiStebimasis tyrimas
1 Day – 17 Years · Visoms lytims · Atnaujinta 2026-08-14 · NCT06274788A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-07-28 · NCT07020533A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-05-18 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 13 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-24 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 40 · Visoms lytims · Atnaujinta 2026-03-12 · NCT05292664CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-03-10 · NCT06059391Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-04-15 · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2024-12-06 · NCT05476770Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.